OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
OPKO Health reported Q2 2026 revenue of $163.5 million, up from $156.8 million in the prior year, while significantly narrowing its net loss to $8.4 million, or $0.01 per share, compared to a loss of $148.4 million last year. The company issued financial guidance for full-year 2026 with total revenue expected between $560 million and $585 million, and noted it repurchased $13.2 million of shares during the quarter, leaving approximately $94.7 million authorized for future buybacks.
Key figures
- Revenue
- 163500000
- Guidance
- FY 2026 Total Revenue $560M-$585M; Q3 2026 Total Revenue $131M-$142M
- Cash position
- 314400000
- Operating loss
- -7000000
- Revenue ip other
- 46100000
- Revenue products
- 42900000
- Revenue services
- 74500000
- Shares repurchased q2
- 13200000
- Buyback authorization remaining
- 94700000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.